Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

'Broccoli drug' may treat osteoarthritis
broccoli
The beneficial effects of broccoli are due to sulforaphane, a compound released during digestion.

Positive results for new drug tested at the RVC

A chemical found in broccoli could offer a treatment for osteoarthritis, after a new drug has been successfully trialled for the first time at the Royal Veterinary College (RVC).

Eating cruciferous vegetables such as sprouts, cabbages and particularly broccoli has been found to ease the symptoms of osteoarthritis. However, patients would have to eat a substantial amount each day to see any real benefits.

The advantages of broccoli are due to sulforaphane, a compound released from the vegetable during digestion, which blocks certain enzymes that destroy joint cartilage. It also obstructs processes that cause the inflammation linked to osteoarthritis.

It had proved impossible to manufacture sulforaphane into a regular pill as it is an unstable molecule.

However, working alongside the RVC, UK pharmaceutical company Evgen Pharma has developed a stable, synthetic version of the compound and incorporated it into a new medicine called Sulforadex (SFX-01). Just a single dose of this medication provides as much sulforaphane as 2.5kg of broccoli.

Osteoarthritis affects nearly nine million people in the UK, costing the NHS over £5 billion a year. Other than pain relief and joint replacement, there is currently no effective treatment or cure. The RVC's professor of skeletal dynamics, Andrew Pitsillides said there is "massive" potential for SFX-01.

For the first time, the product has been trialled by the RVC using live laboratory mice prone to osteoarthritis.

Osteoarthritic mice treated with SFX-01 were shown to have substantially improved movement, gait balance and bone architecture, compared with the control group that did not receive treatment.

“These initial results are very positive for such an experiment and we have convinced ourselves that sulforaphane is a promising agent for the treatment of osteoarthritis," said Prof Pitsillides.

“However, the clinical development of sulforaphane has been held back by the fact that it is inherently unstable. Thus, SFX-01 is a major advance in this area.”

Further pre-clinical and then human clinical trials are needed now that the product is seen as a viable treatment for the painful joint condition.

Human trials are already underway to further investigate the anti-cancer and anti-inflammatory properties of sulforaphane.

Become a member or log in to add this story to your CPD history

Registrations open for overseas veterinary professionals course

News Story 1
 Registrations are now open for the RCVS CPD course for overseas veterinary professionals, which covers an introduction to the UK veterinary professions.

The course is aimed at overseas-qualified veterinary surgeons and nurses during their first two years of working in the UK, in addition to those considering working here. It provides graduates with the key information and skills required to practice in the UK, as well as helping them understand their legal duties as veterinary professionals.

For more information and to book your place please click here. The course will be held at Belgravia House, London, on Wednesday 12 June.  

Click here for more...
News Shorts
BVA launches award to celebrate young vets

A new award has been launched to celebrate inspirational young vets who are making a difference in their day to day work.

Nominations are now open for the BVA Young Vet of the Year Award, which is the first of its kind. It is open to all vets registered with the RCVS in the first eight years of their careers, working in any veterinary sphere, including clinical practice, research, education or veterinary politics. Organisers are looking for an ‘exceptional young vet’ whose work has benefitted the veterinary community or the workplace.

The awards are open for self-entry and nominations by 1 August 2019. The winner will be announced at London Vet Show on 14 November 2019, where a £1000 cash prize will be awarded, alongside a ‘career enhancing experience’ with Zoetis.